Peter J. Sinclair

TL;DR: O-Aryl, O-alkyl, Oalkenyl and Oalkynylrapamycin derivatives of the general structural Formula I:STR1## have been prepared from suitable precursors by alkylation and/or arylation at C-42 and/ or C-31.

TL;DR: Pyrimidine compounds (Formula I), or their pharmaceutically acceptable salts, hydrates, solvates, crystal forms and individual diastereomers, and pharmaceutical compositions including the same, are inhibitors of tyrosine kinase enzymes, and as such are useful in the prophylaxis and treatment of protein kinase-associated disorders, such as immune diseases, hyperproliferative disorders and other diseases in which inappropriate protein Kinase action is believed to play a role as mentioned in this paper.

TL;DR: The present invention encompasses compounds of Formula I: or pharmaceutically acceptable salts or hydrates thereof, which are useful as selective glucocorticoid receptor ligands for treating a variety of autoimmune and inflammatory diseases or conditions as discussed by the authors.

TL;DR: In this article, the CETP inhibitors of Formula (I), including pharmaceutically acceptable salts of the compounds, are shown to be useful for raising HDL-cholesterol, reducing LDL cholesterol, and for treating or preventing atherosclerosis.